Pluristem Therapeutics Inc (PSTI)

[zzaatt]

No mention of ARS treatment? Is that off the table?

Still on the table!!

Silly me

Don't be so tough on youself! Just read more carefully!

“Regarding our second cell therapy product, PLX-R18, which we are developing for several hematopoietic indications, during the quarter we received Orphan Drug Designation for the treatment of graft failure and incomplete recovery following hematopoietic cell transplantation. We are currently evaluating this novel therapeutic cell therapy product in an open-label Phase I clinical trial being conducted in the U.S. and Israel, and we look forward to data that will help guide our next steps in the development of this promising therapeutic,” Mr. Yanay concluded.

PLX-R18 has a broad spectrum applicability for "hematopoietic indications". That includes suppression of cell production due to ionizing radiation (aka ARS, aka Bone marrow syndrome (sometimes referred to as hematopoietic syndrome) !!!).